Systematic review and narrative summary:treatments for and risk factors associated with respiratory tract secretions (death rattle) in the dying adult by Kolb, Hildegard et al.
 UWS Academic Portal
Systematic review and narrative summary
Kolb, Hildegard; Snowden, Austyn; Stevens, Elaine
Published in:
Journal of Advanced Nursing
DOI:
10.1111/jan.13557
Published: 01/07/2018
Document Version
Peer reviewed version
Link to publication on the UWS Academic Portal
Citation for published version (APA):
Kolb, H., Snowden, A., & Stevens, E. (2018). Systematic review and narrative summary: treatments for and risk
factors associated with respiratory tract secretions (death rattle) in the dying adult. Journal of Advanced Nursing,
74(7), 1146-1462. https://doi.org/10.1111/jan.13557
General rights
Copyright and moral rights for the publications made accessible in the UWS Academic Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
Take down policy
If you believe that this document breaches copyright please contact pure@uws.ac.uk providing details, and we will remove access to the
work immediately and investigate your claim.
Download date: 17 Sep 2019
A
cc
ep
te
d 
A
rt
ic
le
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/jan.13557 
This article is protected by copyright. All rights reserved. 
MRS HILDEGARD  KOLB (Orcid ID : 0000-0001-8879-0702) 
PROFESSOR AUSTYN  SNOWDEN (Orcid ID : 0000-0001-9321-622X) 
Article type      : Review 
Systematic Review and Narrative Summary: Treatments for and Risk 
Factors Associated with Respiratory Tract Secretions (Death Rattle) in the 
Dying Adult 
Running head: Treatments and Risk Factors for Death Rattle 
Authors 
Hildegard KOLB, RN, BSc, MRes, staff nurse in Roxburghe House, NHS Grampian, 
Ashgrove Road, Aberdeen AB25 3AE, 01224 557057, h.kolb@live.com 
Austyn SNOWDEN, RMN, Bsc(hons), PhD, Chair in Mental Health, School of Health and 
Social Care, Edinburgh Napier University, Edinburgh, email a.snowden@napier.ac.uk 
twitter: @austynsnowden Corresponding author 
Elaine STEVENS, RN; MSc (Palliative Care); PG Cert Research Supervision, Programme 
Leader and Lecturer in Adult Health, University of the West of Scotland; twitter: 
@nursespalcare 
Conflict of interest statement 
No conflict of interest has been declared by the authors. 
Funding statement 
This research received no specific grant from any funding agency in the public, commercial, 
or not-for-profit sectors. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
ABSTRACT 
Aim 
To identify effective treatments and risk factors associated with death rattle in adults at the 
end of life. 
 
Background  
The presence of noisy, pooled respiratory tract secretions is among the most common 
symptoms in dying patients around the world. It is unknown if ‘death rattle’ distresses 
patients, but it can distress relatives and clinicians. Treatments appear unsatisfactory, so 
prophylaxis would be ideal if possible.  
 
Design 
Quantitative systematic review and narrative summary following Cochrane Collaboration 
guidelines. 
 
Data sources  
CINAHL, MEDLINE, Health Source Nursing and Web of Science were searched for 
international literature in any language published from 1993 - 2016 using MeSH headings 
and iterative interchangeable terms for ‘death rattle’. 
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Review Methods 
Randomised controlled trials were appraised using the Cochrane Collaboration’s tool for 
assessing risk of bias. Non-randomised studies were assessed using ROBINS-I tool for 
assessing risk of bias in non-randomised studies of interventions. Instances of treatment and 
risk were extracted and relevant key findings extracted in line with Cochrane methods. 
 
Results 
Five randomised trials and 23 non-randomised studies were analysed. No pharmacological or 
non-pharmacological treatment was found superior to placebo. There was a weak association 
between lung or brain metastases and presence of death rattle, but otherwise inconsistent 
empirical support for a range of potential risk factors.  
 
Conclusions 
Clinicians have no clear evidence to follow in either treating death rattle or preventing it 
occurring. However, several risk factors look promising candidates for prospective analysis, 
so this review concludes with clear recommendations for further research. 
 
Summary statement 
Why is this review needed? 
• A Cochrane review from 2008 (last reviewed in 2017) focused solely on randomised 
control trials regarding evidence for pharmacological treatment of death rattle and did 
not examine risk factors or alternative treatments. 
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• Treatment of death rattle with antimuscarinic medication appears unsatisfactory and a 
further review of the literature might uncover different or new pharmacological or 
non-pharmacological treatments. 
• The identification of risk factors associated with death rattle development would 
allow for consideration of prophylactic treatment. 
 
What are the key findings? 
 
• No new approaches to pharmacological treatment were found and no published 
research was discovered concerning effective non-pharmacological treatments and 
nursing interventions. 
• There was a weak but consistent association between brain and/or lung metastases and 
development of death rattle 
• There was no consensus regarding manageable risk factors associated with death 
rattle development in the literature. 
How should the findings be used to influence policy/practice/research/education 
 
• Research is needed to identify risk factors pertaining to death rattle to enable 
prophylactic treatment. 
• Research is needed to determine whether specific techniques for the nursing 
management of death rattle, such as suctioning and positional changes influence 
outcomes. 
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• Research is needed to ascertain whether anti-muscarinic medication is the correct 
treatment for death rattle, as research has not shown that it is superior to placebo. 
 
Keywords 
death rattle, respiratory tract secretions, bronchial secretions, palliative care, terminal care, 
end-of-life care, cholinergic antagonists, nurses/midwives/nursing, literature review, 
systematic review. 
 
INTRODUCTION 
Noisy respiratory tract secretions at the end of life are commonly called ‘death rattle’ (Wee et 
al., 2006a). Death rattle and its associated distress, is experienced around the world. The 
international literature reports a wide-ranging prevalence from 12-80% (Hugel et al., 2006; 
Pace et al., 2009). Death rattle is one of the most common symptoms in dying patients 
alongside pain, nausea, dyspnoea and agitation (Gambles et al., 2009). It is generally treated 
with antimuscarinic medication alongside repositioning of the patient for postural drainage 
and oropharyngeal suctioning if appropriate (Hughes et al., 2000). In addition, explanations 
should be offered to family and friends witnessing death rattle to alleviate distress (Hirsch et 
al., 2012). However, efficacy of both pharmacological and non-pharmacological treatments 
can be inconsistent for patients and the outcome is often perceived as unsatisfying for 
clinicians and relatives alike (Fielding & Long, 2014). 
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Background 
The Oxford Textbook of Palliative Medicine describes death rattle in the following manner: 
‘Inability to clear secretion from the oropharynx and trachea often results in noisy ('rattling') 
respiration as the secretions oscillate up and down in conjunction with expiration and 
inspiration’(Twycross & Lichter, 1999, p.985). 
 
The aetiology of death rattle is disputed. Observing that drug treatments vary in efficacy, 
Bennett (1996) and Wildiers and Menten (2002) concluded that there must be two types of 
death rattle, calling them Type 1 and 2, or real and pseudo death rattle respectively. They 
proposed the first type to be a result of retained upper respiratory tract secretions which 
responds well to treatment with antimuscarinic medication. The second type responds poorly 
to antimuscarinic treatment because it is considered to be a result of accumulated bronchial 
secretions secondary to infection or pulmonary disease. Neither Bennett (1996) nor Wildiers 
and Menten (2002) produced any evidence to support their claims. Nevertheless, the idea that 
there are two types of death rattle was supported by Morita et al. (2004b). They agreed that if 
the patient's inability to expectorate (Type 1) caused death rattle, antimuscarinic drugs were 
expected to be effective, while a different approach would be required in the treatment for 
Type 2 death rattle. 
 
More recently, other authors have questioned the two type model and developed other 
mechanistic theories. Clark and Butler (2009) proposed a three-step mechanism with a 
positive feed-back loop. Because of the inability to cough or swallow secretions pooled, 
leading to a partial airway obstruction resulting in further production of secretions. Manthous 
(2013) considered death rattle to be secondary to dysphagia. He proposed two types of 
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patients: “gurglers” and “non-gurglers”, distinguished by listening with a stethoscope over 
the glottis for gurgling sounds. This method was originally used to predict risk for hospital-
acquired pneumonia (Vazquez et al., 2010), although no study was performed that validated 
this theory for death rattle. Whilst evidence is lacking for any particular typology, dysphagia 
is an undisputed clinical sign of the dying process and is predictive of impending death (Hui 
et al., 2014; Kehl & Kowalkowski, 2013). However, whether it causes or is associated with 
death rattle remains unknown. 
 
Research into treatment for death rattle tends to focus on pharmacological remedies, but 
evidence for their efficacy remains equivocal. As death rattle can be distressing for relatives 
and clinicians alike (Kassam, Koslov, & Mendes, 2009; B. L. Wee et al., 2006a; B. L. Wee, 
Coleman, Hillier, & Holgate, 2006b, 2008), preventing death rattle from happening in the 
first place would appear to be the best course of action. If risk factors could be identified then 
‘at risk’ patients could either be selected for prophylactic treatment or at least closely 
monitored for early intervention where possible (Sheehan et al., 2011). A comprehensive 
review of the literature is therefore required to systematically examine evidence for 
treatments for death rattle and risk factors associated with death rattle.  
 
THE REVIEW 
Aim 
The aim of the systematic review and narrative summary was to identify treatments for death 
rattle and risk factors associated with death rattle. The review questions were: 
1. What treatments are effective for death rattle? 
2. What risk factors are associated with death rattle? 
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Design 
Quantitative systematic review and narrative summary following Cochrane Collaboration 
guidelines. 
 
Search methods 
Electronic databases that cover nursing and medical subject areas were used for the search for 
literature pertaining to respiratory tract secretions in dying people coming to the end of life. 
CINAHL, MEDLINE, Health Source Nursing and Web of Science were selected.  
 
Inclusion and exclusion criteria 
Peer reviewed academic journal articles reporting original research about death rattle in 
human adults published between 1993 - 2016 were included. No restriction was put on 
language. Secondary sources like literature reviews and review articles, comments, expert 
opinions, clinical guidelines, case reports, letters and conference posters were excluded. 
Articles pertaining to children and infants were excluded as adult and paediatric palliative 
care differ in practice (Baba & Hain, 2012).  
 
Database search terms 
A basic search with the term “death rattle” in CINAHL revealed that authors used an array of 
labels for this symptom. Therefore, the advanced search had to encompass this variability. 
The following search terms were used in CINAHL, Health Source Nursing and Web of 
Science: 
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(death rattle OR respiratory secretions OR bronchial secretions OR noisy breathing 
OR pulmonary rattles OR terminal respiratory secretions OR respiratory sounds) 
AND (palliative care OR terminal care OR end of life). 
 
MEDLINE search algorithm and a list of other terms are in supplementary file.  
 
Additional literature 
Leading authors in the field of death rattle research were contacted to find out whether there 
were any unpublished works or ongoing research. Those who responded did not have any 
knowledge of ongoing or unpublished research. During the search, secondary literature was 
scrutinised, to discover primary research literature not retrieved through the database search 
(Polit & Beck, 2012). Through the hand-searching of secondary source reference lists one 
further primary research article was obtained. The full text of one randomised control trial 
could not be retrieved from any database, but was kindly provided by the authors (Likar et 
al., 2002). 
 
Search outcome 
The PRISMA diagram chart in Figure 1 details the stepwise elimination strategy that was 
employed to identify relevant literature. From the original 507 papers identified, 190 
remained after removal of duplicates. Sixty-two papers were selected following title 
screening, of which 37 were primary research reports. Subsequently, nine papers were 
excluded as they did not pertain to the research questions, but focused on perceptions and 
distress of people witnessing death rattle. Twenty-eight articles were included in the review, 
five randomised controlled trials and twenty three other studies. 
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uality appraisal 
Randomised controlled trials were assessed for quality using the Cochrane Collaboration’s 
Risk of Bias Tool (Higgins, 2017) following the method previously used by Wee and Hillier 
(2008) in their Cochrane review ‘Interventions for noisy breathing in patients near to death’. 
The Cochrane Collaboration’s Risk of Bias Tool considers risk in relation to selection, 
reporting, incomplete outcome data and blinding. To check for consistency of judgement two 
authors (HK and ES) assessed the one new RCT conducted since 2008.  
 
For non-randomised studies the Cochrane Collaboration currently recommend ROBINS-I 
tool as developed by Sterne et al., (2016). The ROBINS-I was developed to address the 
problems of interpretation associated the Downs and Black instrument (Downs & Black, 
1998) and the Newcastle-Ottawa Scale (Wells et al., 2013). These tools were Cochrane 
Collaboration’s preferred tools, but suffered from difficulties of consistency of interpretation 
in relation to external validity (Sterne et al., 2016). The ROBINS-I starts from the perspective 
that each study is a pragmatic trial and uses a series of signalling questions to assess the risk 
of bias pre-intervention (eg, selection bias), during intervention (allocation deviation) and 
post-intervention (reporting bias). An overall judgement of bias is recorded as low, moderate, 
serious or critical. Critically biased studies are excluded from review. One author (AS) 
assessed all the included studies, whilst the two other authors (HK & ES) assessed half each. 
There was good agreement between the reviewers (K=0.72, p < 0.001) (Carpentier et al., 
2017).  
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Data abstraction 
Using PICO methodology (Higgins, 2017) the population (country, clinical setting and 
sample size), intervention(s), comparator(s) and outcomes of the treatments for death rattle 
were abstracted from each article. PICO data were recorded in tables consistent with the 
study designs and key findings and discussion points related to the research questions were 
summarised. A Harvest plot was created to visualise the findings of all the studies included in 
this review and GRADE criteria were applied to categorise the level of confidence pertaining 
to each body of evidence where results were consistent (Figure 2). Where different studies 
came to contrary conclusions on the same topic, GRADE criteria were not applicable. All 
data were extracted by HK and AS and double checked by ES. 
 
Synthesis 
This process was undertaken concurrently with the abstraction using the quality appraisal for 
risk of bias discussed above. For the RCTs, summary data were created following the style of 
used by Wee and Hillier (2008) in their systematic review of death rattle (Table 1). For the 
non-randomised studies the key data are illustrated in Table 2. As discussed above, because 
these studies were methodologically and conceptually heterogeneous, a Harvest plot was 
constructed to visualise the whole (Figure 2). 
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RESULTS 
A total of 28 articles were included in the review: 
• five randomised control trials, 
• nine prospective studies and 
• fourteen retrospective medical records reviews. 
 
The narrative summary regarding treatments for death rattle and risk factors associated with 
death rattle is presented next. 
 
What treatments are effective? 
Pharmacological treatments 
Twelve studies focused on the effectiveness of various antimuscarinic drugs or reported on 
antimuscarinic drug comparison trials. In all these studies presence of death rattle was an 
entry criterion. None examined prophylactic treatment, even though treatment with 
antimuscarinic drugs was not expected to remove existing secretions, but prevent new 
secretions from developing (Hughes et al., 2000, Back et al., 2001, Kåss & Ellershaw, 2003, 
Clark et al., 2008).  
 
Despite this knowledge, the entry criterion for all these trials was audible death rattle. An 
exclusion criterion was the simultaneous administration of antimuscarinic drugs for other 
conditions (Likar et al., 2002, 2008, Heisler et al., 2013, Protus et al., 2013). These studies 
reported that immediate effectiveness of treatments ranged from 27-86.4%, delayed effect 
from 33-76% and no effect from 22-58%. The wide range of effectiveness may be due to a 
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lack of an established system regarding inclusion criteria and difficulties in measuring 
outcomes objectively and consistently. 
 
In trials where several drugs were compared, no significant difference in effectiveness 
emerged (Hughes et al., 2000, Kåss & Ellershaw, 2003, Wildiers et al., 2009). The trials 
comparing an antimuscarinic drug to placebo balanced each other out. Likar et al., (2008) 
found in favour of the intervention and Heisler et al., (2013) found in favour of placebo, 
though neither results were statistically significant (figure 2). Further, Hugel et al (2006) 
found glycopyrrolate superior to hyoscine, whereas Back et al (2001) found the opposite. The 
trustworthiness of this body of evidence is moderate to very low and therefore in summary 
the evidence for pharmacological treatment of DR onve established is equivocal at present. 
 
Non-pharmacological management 
In palliative care there are non-pharmacological interventions for the management of death 
rattle, for example, repositioning of the patient and oropharyngeal suctioning (Twomey & 
Dowling, 2013). Although many primary research studies listed repositioning for postural 
drainage as part of caring for patients with death rattle, only Bennett (1996) went into more 
detail. In this research report it was acknowledged that the patient's position might contribute 
to the pooling of secretions, while it was later suggested that repositioning the patient from a 
supine to a lateral or upright position might improve symptoms (Bennett et al., 2002). There 
was no research found regarding repositioning or suctioning in the retrieved articles. 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
What risk factors are associated with death rattle? 
Fourteen studies were concerned with risk factors associated with developing death rattle, 
either as their main objective or as supplementary investigations of cohort characteristics. All 
the studies were biased to a significant degree (Table 2) and so all the putative risk factors 
need further investigation. The most common risk factors are discussed below. 
 
Hydration and fluid retention symptoms 
There is considerable anecdotal evidence that high hydration levels cause patients to be 
susceptible to death rattle (Morita et al., 2004b, Plonk & Arnold, 2005). However, the 
majority of studies designed to test this hypothesis found no relationship between hydration 
levels and the development of death rattle (Ellershaw et al., 1995, Morita et al., 2005, 
Sheehan et al., 2011, Yamaguchi et al., 2012). Only one study investigating the influence of 
hydration on end-of-life symptoms when patients were artificially hydrated with more than 
one litre per day found death rattle scores significantly increased (Nakajima et al., 2013). 
Peripheral oedema, ascites and pleural effusion and their relationship with death rattle were 
investigated in two research studies and no relationships were found (Morita et al., 2004b, 
2005). 
 
Diagnosis, dysphagia and loss of swallow and cough reflex 
Patients with cerebral malignancies were identified to be at greater risk of developing death 
rattle in two studies (Bennett, 1996; Morita et al., 2000). Patients with cerebral malignancies 
may lose their cough and swallowing reflexes and the subsequent dysphagia could be the 
determinant of death rattle (Bennett, 1996, Wildiers & Menten, 2002, Morita et al., 2004b). A 
study that entirely comprised patients with cerebral tumours, reported the lowest death rattle 
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prevalence of all reviewed studies (12%) (Pace et al., 2009). However, given there was no 
comparison in this study and it was not focused on analysing death rattle, there appears to be 
reasonable if low quality evidence that cerebral malignancy appears to convey greater risk of 
developing death rattle. 
 
Pulmonary pathology was also associated with death rattle in four studies (Ellershaw et al., 
1995, Morita et al., 2000, Kåss & Ellershaw, 2003, Morita et al., 2004b). Sheehan et al., 
(2011), by contrast, could not find any association with primary diagnoses. Nevertheless the 
weight of evidence seems to favour pulmonary pathology as a likely risk factor for the 
development of death rattle. 
 
Sex and age 
Four studies reported that sex and age were not statistically associated with death rattle 
(Morita et al., 2000; Sheehan et al., 2011; Wildiers & Menten, 2002). One study described 
that men had a greater risk than women conceding, however, that smoking habits and lung 
malignancies might be the causal explanation (Kåss & Ellershaw, 2003). Another study found 
women at greater risk of developing more severe death rattle symptoms (Likar et al.,2016). 
The evidence on gender and age therefore remains equivocal. 
 
Consciousness level 
Several studies proposed that impaired consciousness levels might contribute to the 
development of death rattle (Bennett, 1996; Clark et al., 2008; Pace et al., 2009). Reduced 
consciousness leads to a reduction of cough and swallow reflexes which in turn could cause 
the accumulation of secretions in the airways. Despite this plausible hypothesis, none of the 
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studies demonstrated causality. Decreased consciousness levels have been found to be a 
highly specific sign of impending death in cancer patients (Hui et al., 2014), but the only 
study investigating consciousness levels and death rattle could not find any association 
(Morita et al., 2000). One study found a statistically significant relationship between 
prevalence of death rattle and disorientation to place, time and/or person (Jakobsson, et al., 
2008), suggesting further study of this area would be worthwhile.  
 
Infection 
Authors who support the classification of type 2 death rattle being infection related (eg 
Bennett, 1996, Wildiers & Menten, 2002) recommend that researchers monitor for 
pneumonia in future studies (Kåss & Ellershaw, 2003). Airway infection was identified as a 
risk factor by Morita et al. (2000) who subsequently showed that patients with pneumonia 
were twice as likely to develop death rattle as patients without infections (Morita et al., 
2004b). More work is needed in this area 
 
Length of stay and prolonged dying phase 
Bennett (1996) showed that patients with longer admissions to in-patient settings were more 
likely to develop death rattle, while there was no significant association in another study 
(Morita et al., 2000). Prolonged dying phase, defined as the hours or days of impending 
death, was reported to be a significant risk factor by Kåss & Ellershaw (2003). 
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Anticholinergic load 
Many drugs administered to patients have an anticholinergic effect. Agar et al. (2009) found 
the anticholinergic load of palliative patients increased over time, especially at the end of life. 
However, higher anticholinergic load did not protect the patients from death rattle as 
anticipated, but increased the likelihood of being treated for it (Sheehan et al., 2011). Given 
anticholinergic (antimuscarinic) medication is used as the primary treatment for death rattle, 
the unexpected finding that high anticholinergic load should be predictive as opposed to 
protective of death rattle warrants further investigation. 
 
DISCUSSION 
This systematic review was conducted to gain a comprehensive overview of the current 
knowledge regarding treatments for death rattle and risk factors associated with death rattle. 
There were very few high quality studies, possibly because of the sensitive nature of the 
study focus and the challenges inherent in palliative care research. It is well known that 
recruitment problems, attrition, access and gatekeeping are enduring barriers to palliative care 
research (Jordhøy et al., 1999; Snowden & Young, 2017). 
 
Different studies used different assessment tools to measure the severity of death rattle. This 
made study comparisons difficult. Further, the studies that reported on the pharmacological 
management of death rattle all used very different treatment regimens regarding doses, 
administration methods and timing of administration (see table 3). This heterogeneity was 
why Wee and Hillier (2008) could not perform a meta-analysis in their Cochrane review. A 
decade later this remains the case. No drug regimen was found to be consistently superior to 
another and none was superior to placebo. This suggests that death rattle may be largely 
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untreatable once established (Wildiers et al., 2009, Hirsch et al., 2012, Lokker et al., 2014). 
However, there have been no trials designed to manage death rattle prophylactically. Given 
that some studies have seen an improvement in the symptom burden (Back et al., 2001, 
Wildiers & Menten, 2002), a more optimistic conclusion is that antimuscarinic medication 
may yet help, but treatment needs to be prophylactic (Mercadante, 2014). Such a study would 
need a clear understanding of who may benefit from prophylaxis as prerequisite.  
 
Unfortunately, there was no conclusive evidence that any of the potential risk factors, 
investigated in the studies appraised here, predicted death rattle development. Although many 
risk factors were examined, results were generally contradictory or the evidence was weak. 
The strongest evidence was for pulmonary pathology or brain metastases. Further 
examination of these candidates would make sense, as would well designed studies 
constructed to examine other suspected risk factors such as cholinergic load or other 
iatrogenic harm.  
 
Finally, the role and benefit of nursing interventions such as suctioning and repositioning 
need further investigation (Ahmedzai et al., 2015), as it remains unclear whether they 
contribute to the relief of the symptom (Bennett, 1996) or to the distress of the patient 
(Morita et al., 2004a). There remains no clear evidence that death rattle distresses the patient. 
Until that evidence emerges researchers should urgently focus on developing the best 
evidence to support prophylaxis, drug and non-pharmacological interventions.  
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Limitations 
An attempt was made to include all international literature pertaining to death rattle by not 
actuating any language restrictions. Two articles published in German were included. 
However, the databases selected mainly record English language publications which may 
have unintentionally excluded relevant literature. The authors would appreciate it if missing 
articles were brought to their attention. 
 
The main limitation was the heterogeneity of the evidence. As well as the wide variety of 
study types and variability of pharmacological treatment regimes, death rattle was not 
measured consistently. In prospective studies noise intensity was most frequently assessed 
using the Victoria Respiratory Congestion Scale (Victoria Hospice Society, 2006; Back et al., 
2001; Morita et al., 2004b; Morita et al., 2005; Wildiers et al., 2009; Yamaguchi et al., 2012; 
Nakajima et al., 2013; Heisler et al., 2013). This tool is typically referred to as “Back's scale” 
after the first group to use it in 2001 for noise level assessment of death rattle (Back et al., 
2001). In other publications the researchers used their own 3 or 5-point scales for noise levels 
(Hughes et al., 2000; Likar et al., 2002, 2008) or 4-point scales for treatment effectiveness 
(Hugel et al., 2006).  
 
Some studies used Yes/No assessments (Bennett, 1996, Morita et al., 2000, Wildiers & 
Menten, 2002). This was especially evident in medical record reviews where only the 
presence or absence of death rattle could be assessed in retrospect but not the noise intensity, 
as this was not commonly documented. In four retrospective record reviews an integrated 
care pathway for end-of-life care (ELCP) was used as a tool to assess symptoms (Ellershaw 
et al., 2001, Fowell et al., 2002, Kåss & Ellershaw, 2003). With the exception of presence or 
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absence of death rattle, it will be difficult for future researchers to situate their work in this 
literature without consensus on more subtle elements of measurement. 
 
CONCLUSIONS 
Death rattle remains difficult to manage pharmacologically and non-pharmacologically. No 
treatment is superior to placebo. Prophylactic action is a more promising project, yet all 
previous high quality trials have waited until death rattle begins before randomising patients 
to treatment or control. Surely a better plan would be to test prophylaxis, but this raises the 
ethical question of who to attempt prophylaxis on. This study has identified consistent but 
low confidence evidence that shows brain and lung pathology may increase likelihood of 
developing death rattle. This is enough evidence to warrant approaching funders to support 
sufficiently powered well controlled studies in these populations. 
 
There was otherwise no evidence that any of the other potential risk factors investigated in 
the studies appraised here could help practice in any way. To help practice, putative risk 
factors need to be unequivocally identified and then mitigated in prospective trials as above. 
The missing link at present remains the identification of such risk factors. The authors’ next 
paper takes up this challenge. A retrospective case note review and binary logistic regression 
was used to quantify the unique contribution of a range of risk factors associated with death 
rattle. This included many of those discussed here as well as some novel variables to 
systematically examine their impact. Until it is established that death rattle is entirely 
harmless such evidence is essential to mitigate the distress it causes to families and clinicians 
around the world. 
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*as assessed by Wee and Hillier (2008) 
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SC subcutaneously 
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Back et 
al. 
(2001) 
UK 
specialis
t 
palliativ
e unit 
Pragmatic 
controlled 
study & 
economic 
analysis 
N=504 
(294+2
10) 
Compariso
n of drug 
treatments. 
M M S S Glycopyrrolat
e 0.2 mg was 
less effective 
at reducing 
death rattle 
than hyoscine 
hydrobromide 
0.4 mg after 
30 min (56% 
vs 27%, p= 
0.002). 
 
Secretions 
from lung 
or 
oropharynx 
in patient 
unconsciou
s or too 
weak to 
cough and 
clear them. 
Bennett 
(1996) 
UK 
hospice 
Retrospect
ive record 
review 
N = 100 Efficacy of 
hyoscine 
hydrobromi
de. 
M M S S No effect. 
Dosage 
greater when 
overall stay 
greater than 9 
days (p= 
0.046) and on 
presence of 
cerebral 
malignancy 
(p= 0.048).  
Loss of 
cough & 
swallow 
reflexes; 
slow 
deterioratio
n; opioids, 
diuretics, 
consciousne
ss levels, 
respiratory 
rate. 
Typology 
of DR (type 
1 & 2)? 
Ellersha
w et al. 
(1995) 
UK 
hospice  
Observatio
nal cohort 
study 
N = 82 Relationshi
p between 
hydration 
levels and 
DR. 
M S S S No 
statistically 
significant 
relationship 
was 
demonstrated 
between the 
level of 
hydration and 
DR
Hydration 
levels. 
Presence of 
DR higher 
at baseline 
(p=0.022) 
in pts with 
lung cancer 
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Ellersha
w et al. 
(2001) 
UK 
hospice 
Retrospect
ive record 
review 
N = 168 Utility of 
integrated 
care 
pathway. 
C S S C Recordings 
for 
uncontrolled 
symptoms 
remained 
highest for 
respiratory 
tract 
symptoms. 
Conscious 
state, bed-
bound, only 
able to take 
sips of 
fluid, 
unable to 
take tablets. 
Fowell 
et al. 
(2002) 
UK 
health 
service 
Retrospect
ive record 
review 
N = 500 Utility of 
integrated 
care 
pathway. 
C S C C Anecdotal 
evidence of 
one 
medication 
being more 
effective than 
others was not 
borne out. 
Conscious 
state, bed-
bound, only 
able to take 
sips of 
fluid, 
unable to 
take tablets. 
Hall et 
al. 
(2002) 
Canada 
five 
long-
term 
care 
facilities 
Retrospect
ive record 
review 
N = 185 Assessment 
of local 
palliative 
care 
practice. 
S S S S Prevalence of 
respiratory 
symptoms was 
higher than in 
cancer 
population  
Cancer 
diagnosis 
Hugel et 
al. 
(2006) 
UK 
palliativ
e care 
unit 
Retrospect
ive record 
review 
(second 
arm of 
Kåss & 
Ellershaw 
(2003))  
 
N = 72 Compariso
n between 
glycopyrrol
ate and 
hyoscine 
hydrobromi
de.  
M S S S All patients 
in the 
glycoypyrron
ium group 
had some 
response, 
whereas 22% 
patients in 
hyoscine 
group had no 
response 
(p=0.01) 
 
Lung 
cancer 
Hughes 
et al. 
(2000) 
UK 
hospice 
Prospectiv
e 
comparati
ve audit 
N = 111 
(3x37) 
Audit of 
three 
antimuscari
nic 
medications
.  
S S S S No difference 
between anti-
muscarinic 
medications  
Timing of 
administrati
on of 
antimuscari
nic 
medications 
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Jakobsso
n et al. 
(2008) 
Sweden 
county 
Retrospect
ive record 
review 
N = 229 Clinical 
problems at 
the end of 
life in a 
Swedish 
population. 
S M M S DR 
associated 
with 
cognitive 
disorientatio
n (p=0.022) 
but not 
physical 
dependency 
(p=0.3). 
Age, 
physical 
and 
cognitive 
function 
Kåss & 
Ellersha
w (2003) 
UK 
palliativ
e care 
unit 
Retrospect
ive record 
review 
N = 202 DR treated 
with 
hyoscine 
hydrobromi
de 
M S M S 30.5% 
responded 
within four 
hours, 33.9% 
after four 
hours, and 
35.5% died 
with RTS.  
Significant 
risk factors: 
male sex 
(p=0.034), 
prolonged 
dying phase 
(p=0.001), 
lung cancer 
(p=0.003). 
Likar et 
al. 
(2016) 
Austria 
palliativ
e care 
unit 
Prospectiv
e survey 
N = 102 Clinical 
factors 
influencing 
DR in 
palliative 
care cancer 
patients.  
S S S S The great 
majority of the 
variables 
studied 
showed no 
influence on 
the 
development 
of the 
symptom of 
death rattle. 
Severity 
varied; risk 
factor: 
female sex 
(p = 0.034) 
'Bent back' 
pos’n. 
Lundqui
st et al. 
(2011) 
Sweden 
national 
register   
Secondary 
analysis 
retrospecti
ve record 
review 
N =  
2,383 
Compariso
n between 
those 
informed 
about 
imminent 
death and 
those not 
M M S S Knowing 
death was 
imminent 
associated 
with better 
care & more 
PRN 
parenteral 
drugs 
(p<0.001) 
 
Impending 
death. 
Mercada
nte 
(2011) 
Italy 
caregive
rs at 
Retrospect
ive survey 
N = 181 Understand 
the process 
of dying at 
home for 
caregivers 
of 
M S S S DR most 
frequent 
symptom; 
peaceful 
death: more 
medical home 
Level of 
consciousne
ss 
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home terminally 
ill  
visits 
(p=0.001). 
Morita et 
al. 
(2000) 
Japan 
hospice 
Prospectiv
e 
observatio
nal study 
N = 245 Identify 
risk factors 
associated 
with 
persistence 
of death 
rattle 
M M M M DR risk 
factors: brain 
and lung 
malignancies, 
persistent DR: 
pulmonary 
pathology and 
infection. 
Consciousn
ess levels, 
neoplasms 
of brain, 
lung and 
bone, sex, 
age, length 
of stay. 
Morita et 
al. 
(2004) 
Japan 
oncolog
y, 
palliativ
e care 
unit, 
home 
 
Multicentr
e 
prospectiv
e 
observatio
nal study 
N = 310 Risk 
factors, 
incidence 
and 
aetiology of 
DR 
L M M M Independent 
determinants 
were primary 
lung cancer 
(p=0.001), and 
dysphagia 
(p=0.008)… 
…with an 
odds ratio 
of 2.7 [95% 
C.I, 1.1–
6.8] and 3.6 
[1.3–10] 
respectively
. 
Morita et 
al. 
(2005) 
Japan 
oncolog
y, 
palli’ve 
unit and 
home 
Multicentr
e 
prospectiv
e 
observatio
nal study 
N = 226 Relationshi
p between 
hydration 
levels and 
DR. 
L S M S No clear 
association 
between 
hydration 
volume and 
the 
development 
of DR. Only 
patients with 
abdominal 
malignanc’s. 
  
Oral intake 
of fluids, 
intestinal 
obstruction 
Nakajim
a et al. 
(2013) 
Japan 
hospital 
Prospectiv
e 
observatio
nal study 
N = 75 Relationshi
p between 
hydration 
levels and 
DR. 
L M S S DR score 
significantly 
higher in 
hydration 
group (41%) 
than non-
hydration 
group (19%) 
(p=0.036) 
Hydration 
levels. 
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Pace et 
al. 
(2009) 
Italy 
home 
Retrospect
ive record 
review 
N = 169 Understand 
symtomatol
ogy of 
people 
dying from 
brain 
tumours. 
S S S S DR in 12% of 
brain tumour 
patients. Mild 
dehydration 
may help to 
control this 
symptom. 
Hydration 
levels. 
Protus et 
al. 
(2013) 
USA 
hospice 
Retrospect
ive record 
review 
N = 22  Sublingual 
atropine 1% 
solution for 
DR. 
S C S C 19 of 22 
patients 
treated with 
atropine 1% 
had reduction 
DR.  
Loss of 
swallow 
reflex. 
Seah et 
al. 
(2005) 
Singapor
e 
hospital 
Retrospect
ive record 
review 
N = 189 Describe 
common 
symptoms 
at end of 
life 
S S M S DR was 
common. 
Impending 
death. 
Sheehan 
et al. 
(2011) 
Australia 
palliativ
e care 
unit 
Retrospect
ive record 
review 
N = 199 Explore 
comorbiditi
es, 
anticholiner
gic load, 
and other 
factors of 
DR 
L M M M Patients with a 
higher 
anticholinergi
c load more 
likely to 
require 
treatment for 
DR (odds ratio 
[OR] = 2.9, 
95% 
confidence 
interval [CI] 
=1.4–5.7).  
 
Anticholine
rgic load, 
sex, age, 
diagnosis, 
metastases, 
past 
medical 
history, 
hydration. 
Wildiers 
& 
Menten 
(2002) 
Belgium 
Pall’ve 
care 
Retrospect
ive record 
review 
N = 107 effectivenes
s of 
hyoscine 
hydrobromi
de 
 
M S M S In most cases 
of DR, 
hyoscine 
hydrobromide 
was effective. 
In 75% of the 
patients, DR 
disappeared 
completely.  
Decreased 
consciousne
ss. Too 
weak to 
expectorate. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Study, 
country 
and 
setting 
Design Sample Focus Bias: C= critical 
risk, S = serious 
risk, M = 
moderate risk, L 
= Low risk 
Key finding Risks 
discussed 
Yamagu
chi et al. 
(2012) 
Japan 
oncolog
y and 
palliativ
e care in 
hospital 
and at 
home 
Multicentr
e, 
prospectiv
e, 
observatio
nal study  
N = 161 Effect of 
parenteral 
hydration 
therapy on 
symptom 
intensity in 
patients 
with 
advanced 
cancer. 
L M M M Prevalence of 
DR in the last 
48 hours 
higher in the 
large-volume 
hydration 
group than in 
the small-
volume 
hydration 
group 
(p=0.073). 
Hydration 
levels 
DR death rattle. CPR cardiopulmonary resuscitation 
 
Table 2. Summary of findings from non-randomised studies including ROBINS-I risk of bias (overall 
judgement in bold). 
 
Table 3. Drug regimes of pharmacological treatment trials 
 
 Hyoscine 
Hydrobromide 
(HH) 
Glycopyrronium 
Bromide (GB) 
Hyoscine 
Butylbromide 
(HB) 
Octreotide 
(OCT) 
Atropine 
(AT) 
Placebo 
 
Hughes et 
al., 2000 
 
0.4mg SC, 
30min intervals 
0.6mg 
SC+2.4mg SC/ 
24hrs 
0.6mg SC 
0.2mg SC GB 
0.4mg SC GB 
0.4mg SC GB 
 
 
0.2mg SC, 30min 
intervals 
0.4mg SC+0.6mg 
SC/24hrs 
0.4mg SC 
0.4mg SC GB 
0.4mg SC GB 
0.4mg SC GB 
20mg SC, 
30min 
intervals 
20mg 
SC+20mg SC/ 
24hrs 
20mg SC 
0.2mg SC GB 
0.4mg SC GB 
0.4mg SC GB 
 
Back et al., 
2001 
0.4mg SC, 
30min 
0.4mg SC 
(1.2mg-2.4mg 
SC/ 24hrs) 
 
0.2mg SC, 30min
0.2mg SC 
(0.8mg SC/ 
24hrs) 
 
 
Likar et al., 
2002 
0.5mg SC/IV 
every 4hrs 
    Saline 
SC/IV 
every 4 hrs 
x3 
0.5mg 
SC/IV HH 
every 4hrs 
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 Hyoscine 
Hydrobromide 
(HH) 
Glycopyrronium 
Bromide (GB) 
Hyoscine 
Butylbromide 
(HB) 
Octreotide 
(OCT) 
Atropine 
(AT) 
Placebo 
 
Wildiers & 
Menten, 
2002 
 
0.25mg SC 
every 4 hrs or: 
1-2.5mg IV/ 
24hrs 
 
 
  
Kåss & 
Ellershaw, 
2003 
0.4mg 
SC+1.2mg SC/ 
24hrs; 24hrs: 
2.4mg SC/ 
24hrs 
 
  
Hugel et al. 
2006 
0.4mg 
SC+1.2mg SC/ 
24hrs +prn 
0.4mg SC; if 
prns used in 
24hrs: 2.4mg 
SC/ 24hrs 
0.2mg SC+0.6mg 
SC/ 24hrs+prn 
0.2mg SC; if prns 
used in 24hrs: 
1.2mg SC/ 24hrs 
 
    
Clark et al., 
2008 
0.4mg SC, 
after 1hr: 
0.2mg SC OCT 
 
 0.2mg SC, 
after1hr: 
0.4mg SC 
HH 
 
Likar et al., 
2008 
0.5mg IV 
every 6hrs x3 
 
0.4mg IV 
every 6hrs x3 
 
 
Wildiers et 
al., 2009 
 
0.25mg 
SC+1.5mg SC/ 
24hrs; 
after12hrs: 
0.25mg 
SC+3mg 
SC/24hrs 
 
 
 
20mg 
SC+60mg SC/ 
24hrs 
after12hrs: 
20mg 
SC+120mg 
SC/24hrs 
0.5mg 
SC+3mg 
SC/ 24hrs 
after12 hrs: 
0.5mg SC 
+6mg SC 
/24hrs 
 
Protus et 
al., 2013 
    1mg SL (2 
drops) 
every 2hrs 
prn 
 
 
Heisler et 
al., 2013 
    1mg SL 
(2 drops) 
x1 
2 drops SL 
x1 
 
IV: intravenous; SC: subcutaneous; SL: sublingual; prn: as required medication; HH: Hyoscine Hydrobromide; 
GB: Glycopyrronium Bromide; HB: Hyoscine Butylbromide; OCT: Octreotide; AT: Atropine. 
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